Strides Pharma Science Quarterly Results for Trading Insights
In Mar 2026, Strides Pharma Science (STAR) reported revenue ₹1,333 Cr and net profit ₹129 Cr — revenue +10.5% YoY. Analyse Strides Pharma Science ownership structure to track promoter, FII and institutional holdings.
STAR Quarterly Results — Revenue, Profit & EPS Highlights
Strides Pharma Science latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. View STAR yearly price range for the annual high/low range and current price position.
- Revenue of ₹1,333 Cr in Mar 2026 (-0.1% vs Jun 2026, +10.5% vs Mar 2025)
- Net Profit of ₹129 Cr in Mar 2026 (-22.3% vs Jun 2026, +50.0% vs Mar 2025)
- EBITDA of ₹243 Cr in Mar 2026 (-18.2% vs Jun 2026)
- Operating Margin of 18.0% in Mar 2026 (+0.0pp vs Jun 2026)
- Earnings Per Share of ₹13.77 in Mar 2026 (-19.1% vs Jun 2026)
Strides Pharma Science Quarterly Results — Revenue, EBITDA, Net Profit & EPS
STAR quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | Jun 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 1,333 | 1,334 | 1,248 | 1,206 | 1,128 | -0.1% | 10.5% |
| Net Profit (₹ Cr) | 129 | 166 | 132 | 86 | 106 | - | - |
| EBITDA (₹ Cr) | 243 | 297 | 249 | 206 | 218 | - | - |
| EPS (₹) | 13.77 | 17.02 | 13.84 | 8.92 | 10.81 | - | - |
| Operating Margin (%) | 18.0% | 18.0% | 18.0% | 16.0% | 19.0% | - | - |
STAR Share Price Trend — 1-Year Movement Across Quarterly Results
Strides Pharma Science 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit Strides Pharma Science screener.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
STAR vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Strides Pharma Science latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹441,477.63 Cr | 1837.3 | 15,018 | 2,710 | -5.6% | - | 18.0% | 162.6 |
|
Divis Laboratories
Mar 2026 |
₹247,469.81 Cr | 9375.0 | 2,986 | 751 | -5.0% | - | 25.2% | 331.2 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4840.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 420.5 |
|
Zydus Life Science
Mar 2026 |
₹112,607.65 Cr | 1160.0 | 7,569 | 1,341 | -4.3% | - | 17.7% | 91.7 |
|
Cipla
Mar 2026 |
₹109,705.39 Cr | 1394.5 | 6,612 | 543 | -9.3% | - | 8.2% | 203.0 |
All amounts in ₹ Crores